Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lactobacillus reuteri and metabolite thereof in preparation of medicine for treating liver cancer

A Lactobacillus reuteri, liver cancer treatment technology, applied in the field of biomedicine, can solve the problems of few anti-liver cancer drugs, limited clinical curative effect, and the 5-year survival rate of liver cancer patients is less than 20%, achieving small side effects and safety High, the effect of delaying tumor progression

Pending Publication Date: 2022-05-31
JIANGSU CANCER HOSPITAL
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are very few anti-liver cancer drugs approved by the FDA, only Sorafenib and Regorafenib, and the clinical efficacy is still limited. , clinical drug resistance has also developed into the norm, and monotherapy has been limited. Therefore, it is of great significance to research and develop a new drug or use a combination of drugs to treat tumor growth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactobacillus reuteri and metabolite thereof in preparation of medicine for treating liver cancer
  • Application of lactobacillus reuteri and metabolite thereof in preparation of medicine for treating liver cancer
  • Application of lactobacillus reuteri and metabolite thereof in preparation of medicine for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. The test of the therapeutic effect of Lactobacillus reuteri on liver cancer

[0035] 1.1 Experimental method

[0036] 1.1.1 Establishment of hepatocellular carcinoma model in mice: 2-week-old B6 mice were intraperitoneally injected with DEN (25 mg / kg), once injected, and 6 weeks later, intraperitoneally injected with CCl 4 (2mL / kg, dissolved in corn oil in a volume ratio of 1:4) twice a week, injected with CCl 4 12 weeks total.

[0037] 1.1.2 Lactobacillus reuteri culture: Weigh 63.3 g of MRS medium, add it to 1 L of distilled water, heat and boil to dissolve, divide into packages, and sterilize by autoclaving at 121°C for 15 minutes for later use. Culture temperature: 37°C, culture time: 24-48h.

[0038] 1.1.3 Fecal bacteria transplantation: Mice were treated with antibiotics for 4 days before the fecal transplantation experiment (contained in drinking water: vancomycin: 0.5 mg / mL; imipenem: 0.5 mg / mL; neomycin: 1 mg / mL). Collect the feces of liver cancer mice...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of lactobacillus reuteri and metabolites thereof in preparation of a medicine for treating liver cancer, and belongs to the technical field of biological medicine, when the lactobacillus reuteri is used for treating the liver cancer, the content of acetate is increased, liver injury is improved, and tumor progression of mice with the liver cancer is delayed. When the metabolite of the lactobacillus reuteri is used for treating the liver cancer, the growth of the liver cancer can be effectively inhibited, and especially when the metabolite of the lactobacillus reuteri and an immune checkpoint inhibitor are combined for treating the liver cancer, the aim of synergistically treating the liver cancer can also be achieved. The invention provides a new thought and a more economic therapeutic drug for liver cancer treatment, and lactobacillus reuteri and acetate are taken as endogenous substances of a human body, so that the therapeutic drug has small toxic and side effects and high safety, and a theoretical basis is provided for development of new drugs.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of Lactobacillus reuteri and its metabolites in the preparation of medicaments for treating liver cancer. Background technique [0002] The incidence of liver cancer is on the rise worldwide, and it is estimated that by 2025, 1 million people will suffer from liver cancer every year. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for about 90% of cases, and it is extremely malignant. high and poor prognosis. The pathogenesis of hepatocellular carcinoma is not yet fully understood. At present, it is believed that its pathogenesis is a complex process with multiple factors and steps, which is affected by the dual factors of environment and diet. Aspergillus exposure, smoking, alcohol abuse, obesity, and diabetes are major risk factors for liver cancer. [0003] Due to the insidious onset, rapid growth and poor prognosis of l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747A61K31/19A61K39/395A61P35/00
CPCA61K35/747A61K31/19A61K39/3955A61P35/00A61K2300/00Y02A50/30
Inventor 陈云徐冰清魏良念石林胡楚鹏
Owner JIANGSU CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products